Guidelines on nuclear medicine imaging in neuroblastoma

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):2009-2024. doi: 10.1007/s00259-018-4070-8.

Abstract

Nuclear medicine has a central role in the diagnosis, staging, response assessment and long-term follow-up of neuroblastoma, the most common solid extracranial tumour in children. These EANM guidelines include updated information on 123I-mIBG, the most common study in nuclear medicine for the evaluation of neuroblastoma, and on PET/CT imaging with 18F-FDG, 18F-DOPA and 68Ga-DOTA peptides. These PET/CT studies are increasingly employed in clinical practice. Indications, advantages and limitations are presented along with recommendations on study protocols, interpretation of findings and reporting results.

Keywords: 123I-MIBG; 18F-DOPA PET/CT; 18F-FDG PET/CT; 68Ga-DOTA TATE PET/CT; Children; Guidelines; Neuroblastoma.

MeSH terms

  • 3-Iodobenzylguanidine / metabolism
  • 3-Iodobenzylguanidine / pharmacokinetics
  • Diagnostic Imaging / methods*
  • Humans
  • Neuroblastoma / diagnostic imaging*
  • Neuroblastoma / metabolism
  • Nuclear Medicine*
  • Practice Guidelines as Topic*
  • Radiopharmaceuticals / metabolism
  • Radiopharmaceuticals / pharmacokinetics
  • Tissue Distribution

Substances

  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine